Joshua Schiffman, MD, is the CEO and Co-founder of Peel Therapeutics, a clinical-stage biotech that engineers evolutionary medicines for patients with cancer (“Peel” = Hebrew word for elephant, a naturally cancer resistant animal). The company’s lead asset, PEEL-224, targets TOPO1 activity with a payload designed for better efficacy and less toxicity, and is now in Phase 1B trials for metastatic colorectal cancer. Dr. Schiffman is a Professor of Pediatric Hematology-Oncology and Investigator at Huntsman Cancer Institute at the University of Utah. He holds the Helen Clise Presidential Endowed Chair in Li-Fraumeni Syndrome Research. Dr. Schiffman has published over 200 peer-reviewed articles and book chapters covering topics such as pediatric cancer genomics, precision medicine, hereditary cancer risk, and comparative oncology. Dr. Schiffman graduated from the Brown University School of Medicine in 2000, followed by clinical training in Pediatrics and Pediatric Hematology-Oncology at Stanford University from 2000-2008, and has been at the University of Utah since 2008. Dr. Schiffman is dedicated to improving cancer outcomes through targeted approaches to diagnosis, treatment, and prevention.